PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 87 filers reported holding PMV PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,697,144 | +45.8% | 1,090,740 | +48.7% | 0.08% | +46.3% |
| Q2 2023 | $4,593,181 | +447.5% | 733,735 | +317.2% | 0.05% | +390.9% |
| Q1 2023 | $838,986 | -90.4% | 175,888 | -82.6% | 0.01% | -90.6% |
| Q4 2022 | $8,775,577 | -18.0% | 1,008,687 | +12.2% | 0.12% | -22.0% |
| Q3 2022 | $10,702,000 | +59.8% | 899,307 | +91.4% | 0.15% | +45.6% |
| Q2 2022 | $6,696,000 | -55.2% | 469,883 | -34.6% | 0.10% | -57.6% |
| Q1 2022 | $14,951,000 | +116.7% | 718,093 | +140.5% | 0.24% | +145.5% |
| Q4 2021 | $6,898,000 | -43.2% | 298,610 | -26.7% | 0.10% | -50.0% |
| Q3 2021 | $12,139,000 | +48.6% | 407,365 | +70.4% | 0.20% | +30.3% |
| Q2 2021 | $8,167,000 | +11.0% | 239,081 | +6.9% | 0.15% | -6.7% |
| Q1 2021 | $7,357,000 | -46.8% | 223,690 | -0.5% | 0.16% | -55.6% |
| Q4 2020 | $13,829,000 | +87.8% | 224,821 | +8.4% | 0.37% | +52.3% |
| Q3 2020 | $7,363,000 | – | 207,421 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |